1 The suppression test is reported to have a false-negative rate as high as 50%
Clonidine
FormalPara Interpretation: Criteria for diagnosis of pheochromocytoma : 3 h after clonidine; one of the criteria below confirms the diagnosis : 1
In those patients with a plasma norepinephrine of less than 2000 pg/mL, the clonidine suppression test is 92% accurate in diagnosing pheochromocytoma when the normal
THE diagnosis of pheochromocytoma is considered secure when typical signs and symptoms
Clonidine suppression testing (CST) is recommended to distinguish patients with from those without PPGL
This study
4 If the results are consistent with pheochromocytoma, then conventional
Similarly, the clonidine suppression test cannot be used in patients with rare dopamine secreting pheochromocytomas or
CONCLUSIONS Pheochromocytoma should be suspected in Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension
However, diagnosing adult GHD can be challenging due to the
DSTs are less reliable for the evaluation of the differential diagnosis of corticotropin (ACTH)-dependent
Growth Hormone, Five Specimens (038836) allows five hGH test results: the baseline and four suppression tests
2011; 25:451–456
The test character-istics of 24-hour UFC include sensitivities of 76% to 100% and specificities of 95% to 98%
Aldosterone and renin are measured prior to starting and at the end of the 4 hour infusion
Interpretation: See also Catecholamines, 4-hydroxy-3-methoxymandelate, Homovanillic acid urine, Free metanephrines
Metanephrine levels within the reference range are usually sufficient to exclude PPGLs
Infuse 2 L NS over 4 h
All clonidine suppression tests were carried out after an overnight fast with patients supine
Keep patient supine throughout testing
Orderable Tests: Growth Hormone, Five Specimens (038836) (baseline, 30-, 60-, 90-, and 120-minute) Exercise Stimulation Of 50 patients undergoing both glucagon stimulation and clonidine suppression tests, the results of at least one test were abnormal in 22 of 22 patients with pheochromocytoma (sensitivity 100%) and in 6 of 28 patients without pheochromocytoma (specificity 79%)